Swayze Eric 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Eric Swayze Sells 6,179 Shares After PRSU Vest
What Happened
Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on Jan 29, 2026 (acquired at $0.00). The next day (Jan 30, 2026) he sold 6,179 of those shares in open market transactions for a weighted average price of $82.93, yielding proceeds of approximately $512,446.
Key Details
- Transaction dates: Award/vesting 2026-01-29; open-market sale 2026-01-30.
- Sale detail: 6,179 shares sold at a weighted average price of $82.93 (individual trade prices ranged $82.925–$82.94). Total proceeds ≈ $512,446.
- Award detail: 11,991 PRSUs vested (reported as acquired at $0.00). Compensation Committee certified performance at 167.27% of target based on relative total shareholder return vs. peers; PRSU payout range was 0–200% of target (footnote F1).
- Shares owned after the transactions: Not specified in the provided filing.
- Filing: Report filed 2026-02-02 covering the Jan 29–30, 2026 transactions. The filing does not indicate a late-filing flag.
- Additional note: Reporting person will provide upon request the breakdown of shares sold at each separate price within the reported range (footnote F2).
Context
The award was a performance-based RSU vesting tied to relative total shareholder return (a performance certification triggered a 167.27% payout). The sale occurred the day after vesting and was executed on the open market in multiple trades (weighted average price reported). This summary is factual and does not infer the insider’s motives for selling.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-29+11,991→ 53,926 total - Sale
Common Stock
[F2]2026-01-30$82.93/sh−6,179$512,446→ 47,747 total
- 318(indirect: by Son)
Common Stock
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.925 to $82.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.